Here are the 424B prospectus supplements from SBC Medical Group Holdings Incorporated (SBC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SBC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBC filings page.
SBC Medical Group Holdings Incorporated is registering the resale of 3,100,000 shares of its common stock by the selling stockholder pursuant to this prospectus supplement. The public offering price is $3.25 per share with the selling stockholder receiving the net proceeds; SBC will receive no proceeds. The underwriters have a 45-day option to purchase up to an additional 465,000 shares. Shares outstanding after the offering are stated as 102,576,943 (as of April 16, 2026). The offering is being managed by Maxim Group LLC (book-runner) and Roth Capital Partners (co-manager).
SBC Medical Group Holdings Incorporated discloses a resale offering by a selling stockholder of shares of its common stock; the company states it is not selling any shares hereunder and will receive no proceeds. The prospectus supplement lists a public-market reference price of $4.42 per share (closing price on April 16, 2026) and states there were 102,576,943 shares outstanding as of April 16, 2026. The filing identifies Yoshiyuki Aikawa as the selling stockholder and notes he and entities he controls held approximately 85.2% of voting power as of April 16, 2026. The underwriters have a 45-day option to purchase additional shares; underwriting discounts of 7.0% are disclosed in the underwriting table.